Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 18/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 18/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 14/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.97 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL24670 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL29374525 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL20511531 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616115 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616188 | 0.91 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616237 | 0.90 | ADRA2A (0.83) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616205 | 0.89 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL29227701 | 0.89 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616277 | 0.88 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL20511553 | 0.88 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211672-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2022-07-07 | — | — | US | disclosed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | disclosed |
| US-9138438-B2 | Method for protecting a retinal neuronal cell | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-1864666-B1 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2 ALPHA DERIVATIVE AS ACTIVE INGREDIENT | ASAHI GLASS CO LTD (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120010288-A1 | Method for protecting a retinal neuronal cell | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20090234005-A1 | Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1864666-A1 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2 ALPHA DERIVATIVE AS ACTIVE INGREDIENT | Asahi Glass Company, Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-0630262-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5296228-A | Storage stable compound drug delivery | ALLERGAN, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| WO-1993017716-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010288-A1 | Method for protecting a retinal neuronal cell | ALDH1A2, PTGS2, PTGS1 | ADRA2A 1003/4885ADRA2B 1134/4885ADRA2C 1940/4885 |
| US-20090234005-A1 | Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient | PTGS1, PTGS2, PTGDR2 | ADRA2A 1990/4885ADRA2B 2097/4885ADRA2C 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.